Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zenocutuzumab + enzalutamide
- Development stage
- Unknown
- Lead developer
- Merus
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Zenocutuzumab + enzalutamide is an investigational combination therapy comprising **zenocutuzumab**, a bispecific monoclonal antibody that targets the HER2 and HER3 receptors and inhibits neuregulin 1 (NRG1) fusion oncogenic signaling, and **enzalutamide**, a next-generation androgen receptor (AR) signaling inhibitor. Zenocutuzumab blocks NRG1-driven tumor growth by preventing HER2/HER3 dimerization and signaling, while also recruiting immune effector cells to destroy tumor cells. Enzalutamide antagonizes the androgen receptor, inhibiting androgen-dependent cell proliferation. This combination is under clinical investigation for **metastatic castration-resistant prostate cancer (mCRPC)** to potentially overcome resistance and enhance antitumor effects, especially in patients who have progressed on AR path inhibitors[1][3][5].
- Other names
- Zenozenocutuzumab + enzalutamide
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)AR (Adrenergic receptors)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on zenocutuzumab + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zenocutuzumab + enzalutamide.